Sales are too small to warrant action. The Q1 earnings showed a revenue decline and margin compression from an inventory reserve charge — monitor next quarter for Tyvaso DPI growth trajectory and cost normalization. No trading signal from this insider cluster.
Price Chart
Executive Summary
UTHR's CEO, CFO, and a director sold shares worth $271K in aggregate over a week following Q1 2026 earnings that showed a 2% revenue decline and 15% net income drop. The dollar amount is trivial (0.001% of market cap), the sales are mixed with option exercises (T-code S on exercised shares), and the earnings miss was modest — no material trading signal.
Key Financial Metrics
Key Facts
- Three insiders (CEO, CFO, director) sold an aggregate of $271K in open-market sales over 7 days
- Total sales represent ~0.001% of UTHR's $24.1B market cap — economically trivial
- All CEO and CFO sales were paired with option exercises (T-code S, not P) — pre-planned disposition of derivative shares to cover tax/exercise cost, not opportunistic selling
- Q1 2026 revenue declined 2% YoY to $781.5M; net income declined 15% to $274.9M; EPS missed analyst expectations modestly
- Tyvaso DPI continued growing (+9%), offset by Nebulized Tyvaso decline (-22%) and higher cost of sales ($26.8M inventory reserve charge)
Financial Impact
$271K total insider sales on a $24.1B market cap — trivial
Risk Factors
- Tyvaso DPI growth could slow under competitive pressure from inhaled prostacyclins
- Inventory reserve charge may recur if supply agreement terms shift
- Nebulized Tyvaso erosion may accelerate if patients convert more slowly than expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1779222800564 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $552.73 (+10.47%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $552.73 (+11.19%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $552.73 (+9.70%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $552.73 (+9.06%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $552.73 (+13.36%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $552.73 (+13.23%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $552.73 (+7.23%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $552.73 (+4.70%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $552.73 (+6.98%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $552.73 (+6.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access